Trial Profile
A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 30 Jul 2009 New trial record